https://www.yiliao.com/index.php?action=history&feed=atom&title=%E8%82%BA%E9%B3%9E%E7%99%8C
肺鳞癌 - 版本历史
2026-04-17T17:14:46Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E8%82%BA%E9%B3%9E%E7%99%8C&diff=315681&oldid=prev
2026年1月26日 (一) 01:17 77921020
2026-01-26T01:17:04Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2026年1月26日 (一) 01:17的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l171" >第171行：</td>
<td colspan="2" class="diff-lineno">第171行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">鉴别诊断</td></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">鉴别诊断</td></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px 15px; color: #334155;">p40/p63 阳性 <del class="diffchange diffchange-inline">$\rightarrow$ </del>鳞癌 • TTF-1 阳性 <del class="diffchange diffchange-inline">$\rightarrow$ </del>腺癌</td></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px 15px; color: #334155;">p40/p63 阳性 <ins class="diffchange diffchange-inline">→ </ins>鳞癌 • TTF-1 阳性 <ins class="diffchange diffchange-inline">→ </ins>腺癌</td></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </tr></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </table></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </table></div></td></tr>
</table>
77921020
https://www.yiliao.com/index.php?title=%E8%82%BA%E9%B3%9E%E7%99%8C&diff=315680&oldid=prev
2026年1月26日 (一) 01:14 77921020
2026-01-26T01:14:56Z
<p></p>
<a href="https://www.yiliao.com/index.php?title=%E8%82%BA%E9%B3%9E%E7%99%8C&diff=315680&oldid=311846">显示更改</a>
77921020
https://www.yiliao.com/index.php?title=%E8%82%BA%E9%B3%9E%E7%99%8C&diff=311846&oldid=prev
223.160.136.187：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2025-12-30T05:59:19Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>肺鳞癌</strong>（Lung Squamous Cell Carcinoma, LUSC），是肺癌中非小细胞肺癌（NSCLC）的主要组织学类型之一，约占所有肺癌的 25%-30%。该病与<strong>长期吸烟</strong>高度相关，多起源于大气道段支气管的上皮细胞，具有向鳞状上皮分化的特征（如角化珠形成、细胞间桥）。在分子层面，肺鳞癌表现为极高的突变负荷及显著的拷贝数变异，常见驱动改变包括 <strong>TP53</strong> 突变、<strong>[[FGFR1]]</strong> 扩增及 <strong>[[SOX2]]</strong> 扩增。临床上，肺鳞癌常表现为中央型占位，易发生坏死和空洞形成。随着 <strong>[[Pembrolizumab]]</strong> 联合化疗方案的普及，晚期肺鳞癌的生存预后在近五年得到了显著改善。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible" style="width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">肺鳞癌 · 疾病档案</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Lung Squamous Cell Carcinoma Profile</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
[Microscopic view of keratinization and intercellular bridges in LUSC]<br />
[[文件:LUSC_Histopathology.png|130px|肺鳞癌组织病理学特征]]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">高度吸烟相关的上皮恶性肿瘤</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc; width: 40%;">ICD-11 编码</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">2C25.2</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">关键驱动基因</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;"><strong>[[TP53]]</strong>, <strong>FGFR1</strong>, <strong>PIK3CA</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">谱系致癌基因</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;"><strong>[[SOX2]]</strong> (3q扩增)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">核心病理标志</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">p40(+), CK5/6(+), p63(+)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">Entrez ID (FGFR1)</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">2260</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">常见临床分布</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">中央型 (段以上支气管)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; color: #475569; background-color: #f8fafc;">性别倾向</th><br />
<td style="padding: 8px 12px; color: #0f172a;">男性显著多于女性</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：多阶段演变与通路失调</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
肺鳞癌的发生是一个受环境因素驱动的慢性、多步骤过程，其基因组特征与肺腺癌存在显著差异：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>吸烟相关的基因突变：</strong> 烟草中的致癌物（如多环芳烃）导致 <strong>[[TP53]]</strong> 基因发生高频错义突变（>80%）。此外，LUSC 具有显著的“吸烟签名”（Smoking Signature），表现为 C:G → A:T 的碱基置换。</li><br />
<li style="margin-bottom: 12px;"><strong>3q 染色体扩增：</strong> 这是肺鳞癌最特征性的拷贝数变异。该区域包含了 <strong>[[SOX2]]</strong>（维持鳞状细胞干性）、TP63 和 PIK3CA。这些基因的联合扩增驱动了支气管上皮向鳞状化生及恶性转化的过程。</li><br />
<li style="margin-bottom: 12px;"><strong>RTK/RAS/PI3K 通路激活：</strong> 约 20% 的患者存在 <strong>FGFR1</strong> 扩增，约 15% 存在 PIK3CA 突变。与腺癌不同，LUSC 极少发生 EGFR 敏感突变或 ALK 重排。</li><br />
<li style="margin-bottom: 12px;"><strong>氧化应激应答：</strong> KEAP1-NRF2 通路的突变（约 30%）赋予了鳞癌细胞更强的抗氧化压力能力，使其在缺氧或化疗压力下更易存活。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床评价：分期与诊断路径</h2><br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">诊断环节</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">关键技术手段</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床意义</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">影像学表现</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">增强 CT / PET-CT</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">典型表现为靠近肺门的肿块，边缘毛刺，常伴有阻塞性肺炎或巨大空洞（坏死所致）。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">病理确诊</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">支气管镜活检 / 免疫组化</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">通过 <strong>p40(+)</strong> 和 <strong>TTF-1(-)</strong> 与肺腺癌鉴别。鳞癌细胞较大，胞质丰富。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">生物标志物检测</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">PD-L1 (22C3) / TMB</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">预测免疫治疗效果。肺鳞癌通常具有较高的 TMB，是 <strong>[[Pembrolizumab]]</strong> 的优势人群。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗策略：从化疗基石到免疫联合</h2><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>免疫+联合化疗（标准一线）：</strong> <br />
根据 KEYNOTE-407 研究，无论 PD-L1 表达如何，<strong>[[Pembrolizumab]] + [[紫杉醇联合治疗|紫杉醇]] / 白蛋白紫杉醇 + 卡铂</strong> 已成为晚期肺鳞癌的一线标准治疗方案。</li><br />
<li style="margin-bottom: 12px;"><strong>化疗方案选择：</strong> <br />
鳞癌患者对 <strong>[[顺铂]] / 卡铂</strong> 联合 <strong>[[紫杉醇联合治疗|白蛋白紫杉醇]]</strong> 或吉西他滨较为敏感。禁用培美曲塞（其对鳞癌无效且毒性大）。</li><br />
<li style="margin-bottom: 12px;"><strong>抗血管生成药物：</strong> <br />
贝伐珠单抗在鳞癌中因引起致死性咯血风险而被列为<strong>绝对禁忌</strong>。替代方案包括安罗替尼（三线）或内恩达布（联合化疗）。</li><br />
<li style="margin-bottom: 12px;"><strong>放疗与手术：</strong> <br />
早期（I-II期）首选根治性手术。局部晚期（III期）推荐根治性同步放化疗，序贯度伐利尤单抗（PACIFIC 模式）维持治疗。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键关联概念</h2><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>[[SOX2]]：</strong> 3q26 扩增的核心癌基因，决定鳞状细胞表型。</li><br />
<li style="margin-bottom: 12px;"><strong>[[Pembrolizumab]]：</strong> 彻底改写晚期肺鳞癌生存曲线的免疫基石。</li><br />
<li style="margin-bottom: 12px;"><strong>p40 (ΔNp63)：</strong> 诊断肺鳞癌特异性最高的免疫组化标志物。</li><br />
<li style="margin-bottom: 12px;"><strong>中央型肺癌：</strong> 肺鳞癌最常见的解剖定位，常伴支气管阻塞。</li><br />
</ul><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Cancer Genome Atlas Research Network. (2012).</strong> <em>Comprehensive genomic characterization of squamous cell lung cancers.</em> <strong>Nature</strong>. <br><br />
<span style="color: #475569;">[学术点评]：TCGA 肺鳞癌图谱。首次全面揭示了 LUSC 极高的基因组复杂性，并确立了 SOX2 和 FGFR1 作为核心潜在靶点的地位。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Paz-Ares L, et al. (2018).</strong> <em>Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer.</em> <strong>The New England Journal of Medicine (NEJM)</strong>. <br><br />
<span style="color: #475569;">[学术点评]：KEYNOTE-407 研究。证明了在肺鳞癌一线治疗中加入 PD-1 抑制剂能显著延长 OS 和 PFS，确立了当前的全球临床标准。</span><br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
[3] <strong>Travis WD, et al. (2015).</strong> <em>The 2015 World Health Organization Classification of Lung Tumors.</em> <strong>Journal of Thoracic Oncology</strong>. <br><br />
<span style="color: #475569;">[学术点评]：WHO 官方分类。明确了基于免疫组化标志物（p40、TTF-1）对鳞癌进行精确病理分型的必要性。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1.5px solid #0f172a; border-radius: 8px; overflow: hidden; font-size: 0.95em;"><br />
<div style="background-color: #0f172a; color: #ffffff; text-align: center; font-weight: bold; padding: 10px; letter-spacing: 1px;">肺鳞癌 · 知识图谱关联</div><br />
<div style="padding: 15px; background: #ffffff; line-height: 2.2; text-align: center;"><br />
[[NSCLC]] • [[Pembrolizumab]] • [[SOX2]] • [[FGFR1]] • [[TP53]] • [[紫杉醇联合治疗]] • [[p40]] • [[顺铂]]<br />
</div><br />
</div><br />
<br />
</div></div>
223.160.136.187